GLG Partners’s Vanda Pharmaceuticals VNDA Stock Holding History

GLG Partners’s Portfolio VNDA Stock Details VNDA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q2	–	Sell	-21,254	Closed	-$198K	–	513
2015 Q1	$198K	Buy	+21,254	New	+$240K	0.01%	365

Other funds holding VNDA

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

KCM

Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

GLG Partners's VNDA Position: Q2 2015 in Review

GLG Partners sold out of Vanda Pharmaceuticals (VNDA) in Q2 2015, closing a stake of 21,254 shares — an estimated $198K sold.

GLG Partners first reported a position in VNDA in Q1 2015 and held it in 1 quarter. The position peaked at $198K in Q1 2015. 109 funds tracked by Wall St. Rank hold VNDA as of Q2 2015.

GLG Partners reported no remaining Vanda Pharmaceuticals position as of Q2 2015 after selling out during the quarter.
GLG Partners sold 21,254 Vanda Pharmaceuticals shares in Q2 2015, an estimated $198K.
GLG Partners first reported a position in Vanda Pharmaceuticals in Q1 2015 and held it in 1 quarter.
GLG Partners's Vanda Pharmaceuticals position peaked at $198K in Q1 2015.
109 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q2 2015.

Based on GLG Partners's 13F filing for Q2 2015, filed 14 Aug 2015.